Compare ENOV & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENOV | IMTX |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2008 | 2020 |
| Metric | ENOV | IMTX |
|---|---|---|
| Price | $18.25 | $8.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $47.38 | $19.00 |
| AVG Volume (30 Days) | ★ 1.9M | 619.0K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.36 | N/A |
| Revenue Next Year | $5.31 | $25.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.30 | $7.73 |
| 52 Week High | $34.28 | $12.41 |
| Indicator | ENOV | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.42 | 40.04 |
| Support Level | $17.30 | $8.36 |
| Resistance Level | $27.20 | $10.51 |
| Average True Range (ATR) | 0.99 | 0.30 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 34.99 | 14.98 |
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.